, Volume 70, Issue 12, pp 1487–1503 | Cite as

Laxative Abuse

Epidemiology, Diagnosis and Management
  • James L. Roerig
  • Kristine J. Steffen
  • James E. Mitchell
  • Christie Zunker
Therapy in Practice


Laxatives have been used for health purposes for over 2000 years, and for much of that time abuse or misuse of laxatives has occurred. Individuals who abuse laxatives can generally be categorized as falling into one of four groups. By far the largest group is made up of individuals suffering from an eating disorder such as anorexia or bulimia nervosa. The prevalence of laxative abuse has been reported to range from approximately 10% to 60% of individuals in this group. The second group consists of individuals who are generally middle aged or older who begin using laxatives when constipated but continue to overuse them. This pattern may be promulgated on certain beliefs that daily bowel movements are necessary for good health. The third group includes individuals engaged in certain types of athletic training, including sports with set weight limits. The fourth group contains surreptitious laxative abusers who use the drugs to cause factitious diarrhoea and may have a factitious disorder.

Normal bowel function consists of the absorption of nutrients, electrolytes and water from the gut. Most nutrients are absorbed in the small intestine, while the large bowel absorbs primarily water. There are several types of laxatives available, including stimulant agents, saline and osmotic products, bulking agents and surfactants. The most frequently abused group of laxatives are of the stimulant class. This may be related to the quick action of stimulants, particularly in individuals with eating disorders as they may erroneously believe that they can avoid the absorption of calories via the resulting diarrhoea.

Medical problems associated with laxative abuse include electrolyte and acid/base changes that can involve the renal and cardiovascular systems and may become life threatening. The renin-aldosterone system becomes activated due to the loss of fluid, which leads to oedema and acute weight gain when the laxative is discontinued. This can result in reinforcing further laxative abuse when a patient feels bloated and has gained weight.

Treatment begins with a high level of suspicion, particularly when a patient presents with alternating diarrhoea and constipation as well as other gastrointestinal complaints. Checking serum electrolytes and the acid/base status can identify individuals who may need medical stabilization and confirm the severity of the abuse. The first step in treating laxative misuse once it is identified is to determine what may be promoting the behaviour, such as an eating disorder or use based on misinformation regarding what constitutes a healthy bowel habit. The first intervention would be to stop the stimulant laxatives and replace them with fibre/osmotic supplements utilized to establish normal bowel movements. Education and further treatment may be required to maintain a healthy bowel programme. In the case of an eating disorder, referral for psychiatric treatment is essential to lessen the reliance on laxatives as a method to alter weight and shape.


Anorexia Nervosa Eating Disorder Bulimia Nervosa Bisacodyl Eating Disorder Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



No sources of funding were used to assist in the preparation of this review. James Mitchell has received a research grant from GlaxoSmithKline to study orlistat (Alli®). The other authors have no conflicts of interest that are directly relevant to the content of this review.


  1. 1.
    Phelps L, Andrea R, Rizzo FG, et al. Prevalence of self-induced vomiting and laxative/medication abuse among female adolescents: a longitudinal study. Int J Eat Disord 1993; 14: 375–8PubMedCrossRefGoogle Scholar
  2. 2.
    Tozzi F, Thornton LM, Mitchell JE, et al., on behalf of the Price Foundation Collaborative Group. Features associated with laxative abuse in individuals with eating disorders. Psychosom Med 2006; 68: 470–7PubMedCrossRefGoogle Scholar
  3. 3.
    Baker EH, Sandle GI. Complications of laxative abuse. Annu Rev Med 1996; 47: 127–34PubMedCrossRefGoogle Scholar
  4. 4.
    Wills S. Drugs and substance misuse: over-the-counter products. Pharm J 1993; 251: 807–10Google Scholar
  5. 5.
    Marquart LF, Sobal J. Weight loss beliefs, practices and support systems for high school wrestlers. J Adolesc Health 1994; 15: 410–5PubMedCrossRefGoogle Scholar
  6. 6.
    Shelton JH, Santa Ana CA, Thompson DR, et al. Factitious diarrhea induced by stimulant laxatives: accuracy of diagnosis by a clinical reference laboratory using thin layer chromatography. Clin Chem 2007; 53: 85–90PubMedCrossRefGoogle Scholar
  7. 7.
    Keswani RJ, Sauk J, Kane SV. Factitious diarrhea masquerading as refractory celiac disease. South Med J 2006; 99: 293–5PubMedCrossRefGoogle Scholar
  8. 8.
    Vanin JR, Saylor KE. Laxative abuse: a hazardous habit for weight control. J Am Coll Health 1989; 37: 227–30PubMedCrossRefGoogle Scholar
  9. 9.
    Pomeroy C, Mitchell JE, Roerig J, et al. Medical complications of psychiatric illness. Washington, DC: American Psychiatric Publishing, Inc., 2002Google Scholar
  10. 10.
    Seow-Choen F. The physiology of colonic hydrotherapy. Colorectal Dis 2009; 11: 686–8PubMedCrossRefGoogle Scholar
  11. 11.
    Furness JB, Sanger GJ. Intrinsic nerve circuits of the gastrointestinal tract: identification of drug targets. Curr Opinion Pharmacol 2002; 2: 612–22CrossRefGoogle Scholar
  12. 12.
    Galligan J. Pharmacology of synaptic transmission in the enteric nervous system. Curr Opin Pharmacol 2002; 2: 623–9PubMedCrossRefGoogle Scholar
  13. 13.
    Hansen MB. The enteric nervous system I: organization and classification. Pharmacol Toxicol 2003; 92: 105–13PubMedCrossRefGoogle Scholar
  14. 14.
    Camilleri M, Murray JA. Chapter 40: diarrhea and constipation. In: Fauci AS, Braunwald E, Kasper DL, et al., editors. Harrison’s principles of internal medicine. 17th ed. New York: The McGraw-Hill Companies, 2008: 245–54Google Scholar
  15. 15.
    Pasricha PJ. Chapter 37: treatment of disorders of bowel motility and water flux; antiemetics; agents used in biliary and pancreatic disease. In: Brunton L, Lazo J, Parker K, editors. Goodman & Gilman’s the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill Professional, 2006: 983–1008Google Scholar
  16. 16.
    Tonini M, Cipollina L, Poluzzi E, et al. Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics. Aliment Pharmacol Ther 2004; 19: 379–90PubMedCrossRefGoogle Scholar
  17. 17.
    Talley NJ. Serotoninergic neuroenteric modulators. Lancet 2001; 358: 2061–8PubMedCrossRefGoogle Scholar
  18. 18.
    Nguyen NQ, Chapman M, Fraser RJ, et al. Prokinetic therapy for feed intolerance in critical illness: one drug or two? Crit Care Med 2007; 35: 2561–7PubMedCrossRefGoogle Scholar
  19. 19.
    Neims DM, McNeill J, Giles TR, et al. Incidence of laxative abuse in community and bulimic populations: a descriptive review. Int J Eat Disord 1995; 17: 211–28PubMedCrossRefGoogle Scholar
  20. 20.
    Abraham SF, Beumont PJ. How patients describe bulimia or binge eating. Psychol Med 1982; 12: 625–35PubMedCrossRefGoogle Scholar
  21. 21.
    Cooper PJ, Fairburn CG. Cognitive behaviour therapy for anorexia nervosa: some preliminary findings. J Psychosom Res 1984; 28: 493–9PubMedCrossRefGoogle Scholar
  22. 22.
    Mitchell JE, Boutacoff LL, Hatsukami D, et al. Characteristics of 275 patients with bulimia. Am J Psychiatry 1985; 142: 462–85Google Scholar
  23. 23.
    Mitchell JE, Pomeroy C, Seppala M, et al. Diuretic use as a marker for eating problems and affective disorders among women. J Clin Psychiatry 1988; 49: 267–70PubMedGoogle Scholar
  24. 24.
    Steffen KJ, Mitchell JE, Roerig JL. The eating disorders medicine cabinet revisited: a clinician’s guide to ipecac and laxatives. Int J Eat Disord 2007; 40: 360–8PubMedCrossRefGoogle Scholar
  25. 25.
    Steffen KJ, Roerig JL, Mitchell JE, et al. A survey of herbal and alternative medication use among participants with eating disorder symptoms. Int J Eat Disord 2006; 39: 741–6PubMedCrossRefGoogle Scholar
  26. 26.
    Wade TD. A retrospective comparison of purging type disorders: eating disorder not otherwise specified and bulimia nervosa. Int J Eat Disord 2007; 40: 1–6PubMedCrossRefGoogle Scholar
  27. 27.
    Turner J, Batik M, Palmer LJ, et al. Detection and importance of laxative use in adolescents with anorexia nervosa. J Am Acad Child Adolesc Psychiatry 2000 Mar; 39(3): 378–85PubMedCrossRefGoogle Scholar
  28. 28.
    Bytzer P, Stokholm M, Andersen I, et al. Prevalence of surreptitious laxative abuse in patients with diarrhea of uncertain origin: a cost benefit analysis of a screening procedure. Gut 1989; 30: 1379–84PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Duncan A, Morris AJ, Cameron A, et al. Laxative induced diarrhea: a neglected diagnosis. J R Soc Med 1992; 85: 203–5PubMedPubMedCentralGoogle Scholar
  30. 30.
    Harari D, Gurwitz JH, Avorn J, et al. Constipation: assessment and management in an institutionalized elderly population. J Am Geriatr Soc 1994; 42: 947–52PubMedCrossRefGoogle Scholar
  31. 31.
    Talley NJ. Definitions, epidemiology, and impact of chronic constipation. Rev Gastroenterol Disord 2004; 4 Suppl. 2: S3–10PubMedGoogle Scholar
  32. 32.
    Primrose WR, Capewell AE, Simpson GK. Prescribing patterns observed in registered nursing homes and longstay geriatric wards. Age Ageing 1987; 16: 25–8PubMedCrossRefGoogle Scholar
  33. 33.
    Read NW, Krejs GJ, Read MG, et al. Chronic diarrhea of unknown origin. Gastroenterology 1980; 78: 264–71PubMedGoogle Scholar
  34. 34.
    Harris A, Buchanan GN. Melanosis coli is reversible. Colorectal Dis 2009; 11: 788–9PubMedCrossRefGoogle Scholar
  35. 35.
    Greenfeld D, Mickley D, Quinlan DM, et al. Hypokalemia in outpatients with eating disorders. Am J Psychiatry 1995; 152: 60–3PubMedCrossRefGoogle Scholar
  36. 36.
    Eherer AJ, Fordtran JS. Fecal osmotic gap and pH in experimental diarrhea of various causes. Gastroenterology 1992; 103: 545–51PubMedCrossRefGoogle Scholar
  37. 37.
    Phillips S, Donaldson L, Geisler K, et al. Stool composition in factitial diarrhea: a 6-year experience with stool analysis. Ann Intern Med 1995; 123: 97–100PubMedCrossRefGoogle Scholar
  38. 38.
    Duncan A. Screening for surreptitious laxative abuse. Ann Clin Biochem 2000; 37: 1–8PubMedCrossRefGoogle Scholar
  39. 39.
    Fine KD, Santa Ana CA, Fordtran JS. Diagnosis of magnesium-induced diarrhea. N Engl J Med 1991; 324: 1012–7PubMedCrossRefGoogle Scholar
  40. 40.
    Mayo Foundation for Medical Education and Research. Mayo 2010 test catalog. Rochester (MN): Mayo Foundation for Medical Education and Research, 2010Google Scholar
  41. 41.
    Kovacs D, Palmer RL. The associations between laxative abuse and other symptoms among adults with anorexia nervosa. Int J Eat Disord 2004; 36: 224–8PubMedCrossRefGoogle Scholar
  42. 42.
    Lacey JH, Gibson E. Does laxative abuse control body weight? A comparative study of purging and vomiting bulimics. Hum Nutr Appl Nutr 1985; 39: 36–42PubMedGoogle Scholar
  43. 43.
    Bo-Linn GW, Santa Ana CA, Morawski SG, et al. Purging and calorie absorption in bulimic patients and normal women. Ann Intern Med 1983; 99: 14–7PubMedCrossRefGoogle Scholar
  44. 44.
    Pryor T, Wiederman MW, McGilley B. Laxative abuse among women with eating disorders: an indication of psychopathology? Int J Eat Disord 1996; 20: 13–8PubMedCrossRefGoogle Scholar
  45. 45.
    Rosenberg M. Society and the adolescent self-image. Princeton (NJ): Princeton University Press, 1965CrossRefGoogle Scholar
  46. 46.
    Surgenor LJ, Maguire S, Russell J, et al. Self-liking and self-competence: relationship to symptoms of anorexia nervosa. Eur Eat Disord Rev 2007; 15: 139–45PubMedCrossRefGoogle Scholar
  47. 47.
    Bryant-Waugh R, Turner H, East P, et al. Misuse of laxatives among adult outpatients with eating disorders: prevalence and profiles. Int J Eat Disord 2006; 39: 404–9PubMedCrossRefGoogle Scholar
  48. 48.
    Weltzin TE, Bulik CM, McConaha CW, et al. Laxative withdrawal and anxiety in bulimia nervosa. Int J Eat Disord 1995; 17: 141–6PubMedCrossRefGoogle Scholar
  49. 49.
    Wiederman MW, Pryor T. Multi-impulsivity among women with bulimia nervosa. Int J Eat Disord 1996; 20: 359–65PubMedCrossRefGoogle Scholar
  50. 50.
    Favaro A, Santonastaso P. Impulsive and compulsive self-injurious behavior in bulimia nervosa: prevalence and psychological correlates. J Nerv Ment Dis 1998; 186: 157–65PubMedCrossRefGoogle Scholar
  51. 51.
    Mond JM, Hay PJ, Rodgers B, et al. Correlates of self-induced vomiting and laxative misuse in a community sample of women. J Nerv Ment Dis 2006; 194: 40–6PubMedCrossRefGoogle Scholar
  52. 52.
    Haedt AA, Edler C, Heatherton TF, et al. Importance of multiple purging methods in the classification of eating disorder subtypes. Int J Eat Disord 2006; 39: 648–54PubMedCrossRefGoogle Scholar
  53. 53.
    Hatsukami D, Eckert E, Mitchell JE, et al. Affective disorders and substance abuse in women with bulimia. Psychol Med 1984; 14: 701–4PubMedCrossRefGoogle Scholar
  54. 54.
    Mitchell JE, Hatsukami D, Pyle RL, et al. Bulimia with and without a family history of depressive illness. Compr Psychiatry 1986; 27: 215–9PubMedCrossRefGoogle Scholar
  55. 55.
    Cance JD, Ashley OS, Penne MA. Unhealthy weight control behaviors and MDMA ecstasy use among adolescent females. J Adolesc Health 2005; 37: 409PubMedCrossRefGoogle Scholar
  56. 56.
    Hatsukami D, Mitchell JE, Eckert ED, et al. Characteristics of patients with bulimia only, bulimia with affective disorders, and bulimia with substance abuse problems. Addict Behav 1986; 11: 399–406PubMedCrossRefGoogle Scholar
  57. 57.
    Jonas JM, Gold MS, Sweeney D, et al. Eating disorders and cocaine abuse: a survey of 259 cocaine abusers. J Clin Psychiatry 1987; 48: 47–50PubMedGoogle Scholar
  58. 58.
    Johnson CL, Love SQ. Bulimia: multivariate predictors of life impairment. J Psychiatr Res 1985; 19: 343–7PubMedCrossRefGoogle Scholar
  59. 59.
    Latner JD, Vallance JK, Buckett G. Health-related quality of life in women with eating disorders: association with subjective and objective binge eating. J Clin Psychol Med Settings 2008; 15: 148–53PubMedCrossRefGoogle Scholar
  60. 60.
    Anderson CB, Carter FA, McIntosh VV, et al. Self-harm and suicide attempts in individuals with bulimia nervosa. Eat Disord 2002; 10: 227–43PubMedCrossRefGoogle Scholar
  61. 61.
    Duncan A, Forest JAH. Surreptitious abuse of magnesium laxatives as a cause of chronic diarrhea. Eur J Gastroenterol Hepatol 2001; 13: 599–601PubMedCrossRefGoogle Scholar
  62. 62.
    McQuaid KR. Chapter 15: gastrointestinal disorders. In: McPhee SJ, Papadakis MA, editors. CURRENT Medical Diagnosis & Treatment 2010 [online]. Available from URL: [Accessed 2010 Jan 15]
  63. 63.
    Kreek MJ. Constipation syndromes. In: Lewis JH, editor. A pharmacological approach to gastrointestinal disorders. Baltimore (MD): Williams & Wilkins, 1994: 179–208Google Scholar
  64. 64.
    Izzo AA, Gaginella TS, Mascolo N, et al. Recent findings on the mode of action of laxatives: the role of platelet activating factor and nitric oxide. Trends Pharmacol Sci 1998; 19: 403–5PubMedCrossRefGoogle Scholar
  65. 65.
    Willard SG, Winstead DK, Anding R, et al. Laxative detoxification in bulimia nervosa. In: Johnson WG, editor. Advances in eating disorders: bulimia nervosa: perspectives on clinical research and therapy. Greenwich (CT): JAI Press Inc., 1989Google Scholar
  66. 66.
    Coogan PF, Rosenberg L, Palmer JR, et al. Phenolphthalein laxatives and risk of cancer. J Natl Cancer Inst 2000; 23: 1943–4CrossRefGoogle Scholar
  67. 67.
    Cooper GS, Longnecker MP, Peters RK. Ovarian cancer risk and use of phenolphthalein-containing laxatives. Pharmacoepidemiol Drug Saf 2004; 13: 35–9PubMedCrossRefGoogle Scholar
  68. 68.
    US Food and Drug Administration. Laxative drug products for over-the-counter human use; proposed amendment to the tentative final monograph. Fed Regist 1997 Sep 2; 62: 46223–7Google Scholar
  69. 69.
    Dunnick JK, Hardisty JF, Herbert RA, et al. Phenolphthalein induces thymic lymphomas accompanied by loss of the p53 wild type allele in heterozygous p53-deficient +/-mice. Toxicol Pathol 1997; 25: 533–40PubMedCrossRefGoogle Scholar
  70. 70.
    Siegers CP, von Hertzberg-Lottin E, Otte M, et al. Anthranoid laxative abuse: a risk for colorectal cancer? Gut 1993; 34: 1099–101PubMedPubMedCentralCrossRefGoogle Scholar
  71. 71.
    Xing JH, Soffer EE. Adverse effects of laxatives. Dis Colon Rectum 2001; 44: 1201–9PubMedCrossRefGoogle Scholar
  72. 72.
    Saunders DR, Sillery J, Rachmilewitz D, et al. Effect of bisacodyl on structure and function of rodent and human intestine. Gastroenterology 1977; 72: 849–56PubMedGoogle Scholar
  73. 73.
    Sonnenberg A, Müller AD. Constipation and cathartics as risk factors of colorectal cancer: a meta-analysis. Pharmacology 1993; 47 Suppl. 1: 224–33PubMedCrossRefGoogle Scholar
  74. 74.
    Jacobs EJ, White E. Constipation, laxative use, and colon cancer among middle-aged adults. Epidemiology 1998; 9: 385–91PubMedCrossRefGoogle Scholar
  75. 75.
    Nusko G, Schneider B, Ernst H, et al. Melanosis coli: a harmless pigmentation or a precancerous condition? Z Gastroenterol 1997; 35: 313–8PubMedGoogle Scholar
  76. 76.
    Stoll RE, Blanchard KT, Stoltz JH, et al. Phenolphthalein and bisacodyl: assessment of genotoxic and carcinogenic responses in heterozygous p53 (+/-) mice and Syrian hamster embryo (SHE) assay. Toxicol Sci 2006; 90: 440–50PubMedCrossRefGoogle Scholar
  77. 77.
    Nusko G, Schneider B, Schneider I, et al. Anthranoid laxative use is not a risk factor for colorectal neoplasia: results of a prospective case control study. Gut 2000; 46: 651–5PubMedPubMedCentralCrossRefGoogle Scholar
  78. 78.
    Dukas L, Willett WC, Colditz GA, et al. Prospective study of bowel movement, laxative use, and risk of colorectal cancer among women. Am J Epidemiol 2000; 151: 958–64PubMedCrossRefGoogle Scholar
  79. 79.
    Kune GA, Kune S, Field B, et al. The role of chronic constipation, diarrhea, and laxative use in the etiology of large-bowel cancer: data from the Melbourne Colorectal Cancer Study. Dis Colon Rectum 1988; 31: 507–12PubMedCrossRefGoogle Scholar
  80. 80.
    Nascimbeni R, Donato F, Ghirardi M, et al. Constipation, anthranoid laxatives, melanosis coli, and colon cancer: a risk assessment using aberrant crypt foci. Cancer Epidemiol Biomarkers Prev 2002; 11: 753–7PubMedGoogle Scholar
  81. 81.
    Roberts MC, Millikan RC, Galanko JA, et al. Constipation, laxative use, and colon cancer in a North Carolina population. Am J Gastroenterol 2003; 98: 857–64PubMedCrossRefGoogle Scholar
  82. 82.
    Fioramonti J, Bueno L. Toxicity of laxatives: how to discriminate between myth and fact? Eur J Gastroenterol Hepatol 1995; 7: 5–7PubMedGoogle Scholar
  83. 83.
    Muller-Lissner SA, Kamm MA, Scarpignato C, et al. Myths and misconceptions about chronic constipation. Am J Gastroenterol 2005; 100: 232–42PubMedCrossRefGoogle Scholar
  84. 84.
    Drug facts and comparisons 2006. 60th ed. Philadelphia (PA): Lippincott, Williams & Wilkins, 2006Google Scholar
  85. 85.
    Anderson JW, Zettwoch N, Feldman T, et al. Cholesterol-lowering effects of psyllium hydrophilic mucilloid for hyper-cholesterolemic men. Arch Intern Med 1988; 148: 292–6PubMedCrossRefGoogle Scholar
  86. 86.
    Bell LP, Hectorne K, Reynolds H, et al. Cholesterol-lowering effects of psyllium hydrophilic mucilloid: adjunct therapy to a prudent diet for patients with mild to moderate hypercholesterolemia. JAMA 1989; 261: 3419–23PubMedCrossRefGoogle Scholar
  87. 87.
    Levin EG, Miller VT, Muesing RA, et al. Comparison of psyllium hydrophilic mucilloid and cellulose as adjuncts to a prudent diet in the treatment of mild to moderate hypercholesterolemia. Arch Intern Med 1990; 150: 1822–7PubMedCrossRefGoogle Scholar
  88. 88.
    Als-Nielsen B, Gluud LL, Gluud C. Nonabsorbable disaccharides for hepatic encephalopathy. Cochrane Database Syst Rev 2004; 2: CD003044Google Scholar
  89. 89.
    Loening-Baucke V, Pashankar DS. A randomized, prospective, comparison study of polyethylene glycol 3350 without electrolytes and milk of magnesia for children with constipation and fecal incontinence. Pediatrics 2006; 118: 528–35PubMedCrossRefGoogle Scholar
  90. 90.
    Slugg PH, Carey WD. Clinical features and follow-up of surreptitious laxative users. Cleveland Clin Q 1984; 51: 167–71CrossRefGoogle Scholar
  91. 91.
    Krahn LE, Lee J, Richardson JW, et al. Hypokalemia leading to torsades de pointes: Munchausen’s disorder or bulimia nervosa? Gen Hosp Psychiatry 1997; 19: 370–7PubMedCrossRefGoogle Scholar
  92. 92.
    Wright LF, DuVal Jr JW. Renal injury associated with laxative abuse. South Med J 1987; 80: 1304–6PubMedCrossRefGoogle Scholar
  93. 93.
    Vanderperren B, Rizzo M, Angenot L, et al. Acute liver failure with renal impairment related to the abuse of senna anthraquinone glycosides. Ann Pharmacother 2005; 39: 1353–7. Epub 2005 Jun 14PubMedCrossRefGoogle Scholar
  94. 94.
    Qureshi T, Melonakos TK. Acute hypermagnesemia after laxative use. Ann Emerg Med 1996; 28: 552–5PubMedCrossRefGoogle Scholar
  95. 95.
    Corbi G, Acanfora D, Iannuzzi GL, et al. Hypermagnesemia predicts mortality in elderly with congestive heart disease: relationship with laxative and antacid use. Rejuvenation Res 2008; 11: 129–38PubMedCrossRefGoogle Scholar
  96. 96.
    Sebastian AN, Hulter HN, Rector BC. Metabolic alkalosis. In: Brenner BM, Stein JH, editor. Contemporary issues in nephrology, acid-base and potassium homeostasis. New York: Churchill-Livingstone, 1978: 101–36Google Scholar
  97. 97.
    Kobayashi N, Tamai H, Uehata S, et al. Pancreatic abnormalities in patients with eating disorders. Psychosom Med 1988; 50: 607–14PubMedCrossRefGoogle Scholar
  98. 98.
    Brown NW, Treasure JL, Campbell IC. Evidence for long-term pancreatic damage caused by laxative abuse in subjects recovered from anorexia nervosa. Int J Eat Disord 2001; 29: 236–8PubMedCrossRefGoogle Scholar
  99. 99.
    Cummings JH. Laxative abuse. Gut 1974; 15: 758–66PubMedPubMedCentralCrossRefGoogle Scholar
  100. 100.
    Cummings JH, Sladen GE, James OF, et al. Laxative-induced diarrhoea: a continuing clinical problem. BMJ 1974; 23: 537–41CrossRefGoogle Scholar
  101. 101.
    LaRusso NF, McGill DB. Surreptitious laxative ingestion. Delayed recognition of a serious condition: a case report. Mayo Clin Proc 1975; 50: 706–8PubMedGoogle Scholar
  102. 102.
    Cooke WT. Laxative abuse. Clin Gastroenterol 1977; 6: 659–73PubMedGoogle Scholar
  103. 103.
    Kim SK, Gerle RD, Rozanski R. Cathartic colitis. AJR Am J Roentgenol 1978; 131: 1079–81PubMedCrossRefGoogle Scholar
  104. 104.
    Sansone RA. Complications of hazardous weight-loss methods. Am Fam Physician 1984; 30: 141–6PubMedGoogle Scholar
  105. 105.
    Cuellar RE, Van Thiel DH. Gastrointestinal consequences of the eating disorders: anorexia nervosa and bulimia. Am J Gastroenterol 1986; 81: 1113–24PubMedGoogle Scholar
  106. 106.
    Mitchell JE, Seim HC, Colon E, et al. Medical complications and medical management of bulimia. Ann Intern Med 1987; 107: 71–7PubMedCrossRefGoogle Scholar
  107. 107.
    Weiss BD, Wood GA. Laxative abuse causing gastrointestinal bleeding. J Fam Pract 1982; 15: 177–81PubMedGoogle Scholar
  108. 108.
    Mitchell JE, Pyle RL, Eckert ED, et al. Electrolyte and other physiological abnormalities in patients with bulimia. Psychol Med 1983; 13: 273–8PubMedCrossRefGoogle Scholar
  109. 109.
    Wald A. Is chronic use of stimulant laxatives harmful to the colon? J Clin Gastroenterol 2003; 36: 386–9PubMedCrossRefGoogle Scholar
  110. 110.
    Morales MA, Hernández D, Bustamante S, et al. Is senna laxative use associated to cathartic colon, genotoxicity, or carcinogenicity? J Toxicol 2009; 2009: 287247PubMedPubMedCentralCrossRefGoogle Scholar
  111. 111.
    Copeland PM. Renal failure associated with laxative abuse. Psychother Psychosom 1994; 62: 200–2PubMedCrossRefGoogle Scholar
  112. 112.
    Wu WJ, Huang CH, Chiang CP, et al. Urolithiasis related to laxative abuse. J Formos Med Assoc 1993; 92: 1004–6PubMedGoogle Scholar
  113. 113.
    Malik M, Stratton J, Sweeney WB. Rectal prolapse associated with bulimia nervosa: report of seven cases. Dis Colon Rectum 1997; 40: 1382–5PubMedCrossRefGoogle Scholar
  114. 114.
    Mitty RD, Wolfe GRZ, Cosman M. Initial description of gastric melanosis in a laxative-abusing patient. Am J Gastroenterol 1997; 92: 707–8PubMedGoogle Scholar
  115. 115.
    Chan TY. Aconite poisoning. Clin Toxicol 2009; 47: 279–85CrossRefGoogle Scholar
  116. 116.
    Lin CC, Chan TY, Deng JF. Clinical features and management of herb-induced aconitine poisoning. Ann Emerg Med 2004; 43: 574–9PubMedCrossRefGoogle Scholar
  117. 117.
    Riley JA, Brown AR, Walker BE. Congestive cardiac failure following laxative withdrawal. Postgrad Med J 1996; 72: 491–2PubMedPubMedCentralCrossRefGoogle Scholar
  118. 118.
    Harper J, Leung M, Birmingham CL. A blinded laxative taper for patients with eating disorders. Eat Weight Disord 2004; 9: 147–50PubMedCrossRefGoogle Scholar
  119. 119.
    Colton P, Woodside DB, Kaplan AS. Laxative withdrawal in eating disorders: treatment protocol and 3 to 20-month follow-up. Int J Eat Disord 1999; 25: 311–7PubMedCrossRefGoogle Scholar
  120. 120.
    Cooper PJ, Fairburn CG. The eating disorders examination: a semi-structured interview for the assessment of the specific psychopathology of the eating disorders. Int J Eat Disord 1987; 6: 1–8CrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  • James L. Roerig
    • 1
    • 2
  • Kristine J. Steffen
    • 2
  • James E. Mitchell
    • 1
    • 2
  • Christie Zunker
    • 2
  1. 1.Department of Clinical NeuroscienceUniversity of North Dakota School of Medicine and Health SciencesFargoUSA
  2. 2.Neuropsychiatric Research InstituteFargoUSA

Personalised recommendations